Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Phase 3

Terminated

Conditions: Diffuse, Large B-Cell, Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Drug: Bendamustine
Drug: Placebo
Drug: Rituximab

First Posted Date: 2020-01-22

Last Posted Date: 2023-03-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 42

Registration Number: NCT04236141

Locations: 🇨🇳
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China
🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, China

and more 7 locations

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Phase 1

Recruiting

Conditions: Nodal Marginal Zone Lymphoma
Indolent Non-hodgkin Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Splenic Marginal Zone Lymphoma

Interventions: Drug: CAR.k.28
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine

First Posted Date: 2020-01-10

Last Posted Date: 2025-03-03

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04223765

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Relapsed T-Cell Lymphoma
Refractory T-Cell Lymphoma
Non Hodgkin Lymphoma

Interventions: Drug: CPI 613
Drug: Bendamustine

First Posted Date: 2020-01-03

Last Posted Date: 2025-05-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 6

Registration Number: NCT04217317

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Terminated

Conditions: Lymphoid Leukemia
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Copanlisib
Biological: Rituximab
Drug: Bendamustine

First Posted Date: 2019-11-07

Last Posted Date: 2022-04-11

Lead Sponsor: University of Washington

Target Recruit Count: 1

Registration Number: NCT04155840

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Phase 2

Withdrawn

Conditions: PTLD
Lymphoid Tumor
Hematopoietic/Lymphoid Cancer
Plasmacytic Hyperplasia PTLD
Infectious Mononucleosis
Florid Follicular Hyperplasia PTLD
Polymorphic PTLD
Monomorphic PTLD
Classical Hodgkin Lymphoma Type PTLD

Interventions: Drug: Rituximab
Drug: Brentuximab Vedotin
Drug: Bendamustine

First Posted Date: 2019-10-25

Last Posted Date: 2022-06-23

Lead Sponsor: Yale University

Registration Number: NCT04138875

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

Conditions: Mantle Cell Lymphoma

First Posted Date: 2019-10-16

Last Posted Date: 2020-03-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 40

Registration Number: NCT04127916

Locations: 🇰🇷
Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, Korea, Republic of

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Liver Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: Bendamustine
Drug: Acalabrutinib
Drug: Bendamustine Hydrochloride
Drug: Cytarabine
Biological: Rituximab

First Posted Date: 2019-10-04

Last Posted Date: 2024-12-10

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 360

Registration Number: NCT04115631

Locations: 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸
Providence Newberg Medical Center, Newberg, Oregon, United States
🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States

and more 501 locations

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Biological: ATLCAR.CD30 T cells
Drug: Bendamustine
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-09-10

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04083495

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Isatuximab
Drug: Bendamustine
Drug: Prednisone

First Posted Date: 2019-09-10

Last Posted Date: 2024-03-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 15

Registration Number: NCT04083898

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
B-cell Lymphoma

Interventions: Drug: FT516
Drug: Rituximab
Drug: Obinutuzumab
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: IL-2
Drug: Bendamustine

First Posted Date: 2019-07-17

Last Posted Date: 2023-10-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 72

Registration Number: NCT04023071

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy